| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. | President, Head of R&D | Common Stock | 75,000 | $283,500 | $3.78 | 23 Jan 2024 | Direct |
| Terns Pharmaceuticals, Inc. | President, Head of R&D | Stock Option (Right to Buy) | 150,000 | 23 Jan 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| TERN | Terns Pharmaceuticals, Inc. | 23 Jan 2024 | 2 | $0 | 4 | President, Head of R&D | 25 Jan 2024, 19:17 |
| TERN | Terns Pharmaceuticals, Inc. | 01 Feb 2023 | 1 | $0 | 4 | President, Head of R&D | 03 Feb 2023, 17:00 |
| TERN | Terns Pharmaceuticals, Inc. | 26 Jan 2022 | 1 | $0 | 4 | President, CMO and Head of R&D | 28 Jan 2022, 20:02 |
| TERN | Terns Pharmaceuticals, Inc. | 28 Sep 2021 | 1 | $0 | 4 | President and CMO | 30 Sep 2021, 21:14 |